NEW YORK, Jan 3, 2026, 20:43 ET — Market closed
- Kymera Therapeutics shares fell 6.6% on Friday, closing at $72.76.
- A regulatory filing showed CEO Nello Mainolfi exercised options and sold shares on Dec. 31.
- Investors head into Monday watching U.S. jobs data and Kymera’s 2026 clinical-trial timeline.
Kymera Therapeutics shares slid on Friday, ending down 6.6% at $72.76 as the biotech underperformed its sector even as the broader market started 2026 on a mixed note.
The move matters because Kymera has been a high-beta biotech name since a sharp rally in December on early trial data for its KT-621 immunology program, leaving the stock sensitive to profit-taking and fresh supply from capital-raising activity.
With U.S. markets facing a busy week of economic releases, risk appetite has been uneven and investors have leaned on near-term catalysts — or the lack of them — when judging fast-moving growth stocks.
Kymera traded between $72.18 and $78.81 on Friday, with about 854,000 shares changing hands, according to market data.
Biotech benchmarks were steadier: the SPDR S&P Biotech ETF (XBI) slipped 0.3% while the iShares Nasdaq Biotechnology ETF (IBB) edged up 0.1% on the session.
A Form 4 filing showed Kymera CEO Nello Mainolfi exercised options for 30,000 shares and sold 30,000 shares on Dec. 31, with the sales executed under a Rule 10b5-1 plan — a pre-arranged program that can allow insiders to trade on a set schedule.
In its December update on KT-621, Kymera said the oral drug candidate achieved deep STAT6 degradation and reported improvements on biomarkers linked to Type 2 inflammation, which underpins conditions such as atopic dermatitis and asthma.
Kymera has positioned KT-621 — a “protein degrader” designed to reduce levels of a target protein rather than simply blocking it — as a potential oral alternative to injectable standards of care in atopic disease. Dupixent, sold by Regeneron and Sanofi, is one of the established therapies in that space. Investors
The company also said in December that the U.S. FDA granted Fast Track designation to KT-621 for atopic dermatitis, a status that can speed interactions with regulators and, in some cases, review timelines.
Kymera raised cash as it pushed deeper into mid-stage trials, announcing the closing of an upsized $602 million public offering in December.
Before Monday’s session, investors will be watching U.S. economic data for direction, including next week’s jobs report and inflation readings that could shift expectations for Federal Reserve policy. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak, in a Reuters interview on Friday. Reuters
On the company side, Kymera has said it is on track to initiate BREADTH, a Phase 2b trial in asthma, in the first quarter of 2026. The next earnings update has not been formally confirmed, but market calendars cluster Kymera’s next report in late February.
Technically, traders will be watching whether the stock holds above Friday’s low near $72 and the round-number $70 level; a break lower would put the post-rally pullback back in focus, while a rebound would need to reclaim the mid-to-high $70s area to ease near-term pressure.
